RVNC / Revance Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified

AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

EX-99 2 exhibitajointfilingagreement.htm EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3ASR REGISTRATION STATEMENT NO. 333-275548 THE SECURITIES ACT OF 1933 REVANCE THERAPEUTICS, INC. (Exact name of Registrant as specified i

Registration No. 333-275548 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3ASR REGISTRATION STATEMENT NO. 333-275548 UNDER THE SECURITIES ACT OF 1933 REVANCE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 77-0551645 (State or jurisdiction of incorporation or organization) (I.R.S. Employer Identif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490 UNITED S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-8 REGISTRATION STATEMENTS NOS. 333-193963, 333-198499, 333-203235, 333-208543, 333-209949, 333-216342, 333-223433, 333-229977, 333-235994, 3

S-8 POS Registration No. 333-193963 Registration No. 333-198499 Registration No. 333-203235 Registration No. 333-208543 Registration No. 333-209949 Registration No. 333-216342 Registration No. 333-223433 Registration No. 333-229977 Registration No. 333-235994 Registration No. 333-240061 Registration No. 333-252526 Registration No. 333-263099 Registration No. 333-270130 Registration No. 333-277490

FIRST SUPPLEMENTAL INDENTURE

Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of February 6, 2025, between Revance Therapeutics, Inc., a Delaware corporation (the “Issuer”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association, as trustee (the “Trustee”), supplementing

AMENDED AND RESTATED BYLAWS REVANCE THERAPEUTICS, INC. A Delaware Corporation ARTICLE I

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF REVANCE THERAPEUTICS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1. Registered Office. The registered office of Revance Therapeutics, Inc. (the “Corporation”) shall be located at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of the Corporation’s registered agent at such address shall be Corporation Servi

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION REVANCE THERAPEUTICS, INC. ARTICLE ONE

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REVANCE THERAPEUTICS, INC. ARTICLE ONE The name of the corporation is Revance Therapeutics, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at

Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics The business combination reinforces Crown’s position as a leading, innovative, high-growth aesthetics and skincare company

Exhibit 99.1 Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics The business combination reinforces Crown’s position as a leading, innovative, high-growth aesthetics and skincare company Johnson City, Tenn. – February 6, 2025 — Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, today announced the successful closing

EX-99.25

Form 25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) REVANCE THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 7) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer

Exhibit (a)(5)(P) Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer Johnson City, Tenn.

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Exhibit(a)(5)(O) Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline • Crown offer of $3.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 6) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) REVANCE THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Exhibit (a)(5)(E) Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline • Crown offer of $3.

AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER

Exibit 2.1 Execution Version AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of January 17, 2025 (this “Amendment No. 2”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 5) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) REVANCE THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer

Exhibit (a)(5)(N) Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 (January 17, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 (January 17, 2025) Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorpo

Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC CROWN LABORATORIES H

Exhibit 107 Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC.

Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners III-B January 17, 2025

Exhibit (d)(12) Execution Version Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners III-B January 17, 2025 Crown Laboratories, Inc.

AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER

Exhibit (d)(11) Execution Version AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of January 17, 2025 (this “Amendment No. 2”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subs

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer

Exhibit 99.1 Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer • Increased offer price to $3.65 per share, a $0.55 per share increase • Improved offer unanimously approved by Revance Board of Directors • Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4, 2025 • Crown’s offer is the only

SECOND AMENDED AND RESTATED LIMITED GUARANTEE

Exhibit (d)(13) Execution Version SECOND AMENDED AND RESTATED LIMITED GUARANTEE This Second Amended and Restated Limited Guarantee, dated as of January 17, 2025 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP, Hildred Equity Partners III-A, LP and Hildred Equity Partners III-B, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”), is made in favor of Revance Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) REVANCE THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

Exhibit (a)(5)(M) Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

Crown Laboratories, Inc. 207 Mockingbird Lane Johnson City, Tennessee 37604

Exhibit 99.1 CONFIDENTIAL Crown Laboratories, Inc. 207 Mockingbird Lane Johnson City, Tennessee 37604 January 6, 2025 Board of Directors Revance Therapeutics, Inc. 1222 Demonbreun Street Nashville, Tennessee 37203 To the Members of the Board of Directors: We strongly believe that the incomplete, non-binding and highly contingent “proposal” of Teoxane SA (“Teoxane”), dated January 6, 2025 (the “Teo

January 6, 2025

Exhibit 99.1 CONFIDENTIAL January 6, 2025 Angus C. Russell Chairman & Mark Foley Chief Executive Officer Revance Therapeutics, Inc. 1222 Demonbreun St., 20th Floor Nashville, TN 37203 USA Dear Messrs. Russell & Foley, Teoxane SA is pleased to submit this proposal (“Proposal”) to acquire all of the outstanding shares of of Revance Therapeutics, Inc. (“Revance” or the “Company”), other than the shar

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash Compelling Cash Proposal Provides 16% Premium Over Revance’s Amended and Restated Agreement with Crown Laboratories

Exhibit 99.2 FOR RELEASE AT 9:00 AM ET ON JANUARY 6, 2025 Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash Compelling Cash Proposal Provides 16% Premium Over Revance’s Amended and Restated Agreement with Crown Laboratories GENEVA, January 6, 2025 – Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Revance Therapeutics, Inc. (Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) REVANCE THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other

ARES CAPITAL MANAGEMENT LLC 245 Park Avenue, 44th Floor New York, NY 10167

EX-99.(B)(1) Exhibit (b)(1) Execution Version CONFIDENTIAL ARES CAPITAL MANAGEMENT LLC 245 Park Avenue, 44th Floor New York, NY 10167 December 7, 2024 Crown Laboratories Holdings, Inc. c/o Hildred Capital Management, LLC 745 Fifth Avenue Suite 801 New York, NY 10151 Crown Laboratories, Inc. c/o Hildred Capital Management, LLC 745 Fifth Avenue Suite 801 New York, NY 10151 Project Reba Amended and R

Skadden, Arps, Slate, Meagher & Flom llp ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www.skadden.com January 2, 2025

Skadden, Arps, Slate, Meagher & Flom llp ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www.

LIMITED GUARANTEE

Exhibit (d)(8) LIMITED GUARANTEE This Limited Guarantee, dated as of August 11, 2024 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP, Hildred Equity Partners III-A, LP, Hildred Equity Partners II, LP, Hildred Equity Associates II, LP, Hildred Equity Partners II-FR, LP and Hildred Equity Partners II-A, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”) is made in favor of Revance Therapeutics, Inc.

AMENDED AND RESTATED LIMITED GUARANTEE

Execution Version Exhibit (d)(9) AMENDED AND RESTATED LIMITED GUARANTEE This Amended and Restated Limited Guarantee, dated as of December 7, 2024 (this “Limited Guarantee”), by Hildred Perennial Partners I, LP, Hildred Capital Co-Invest-REBA, LP, Hildred Equity Partners III, LP and Hildred Equity Partners III-A, LP, each a Delaware limited partnership (each of the foregoing, a “Guarantor” and collectively, the “Guarantors”) and solely for the purposes of Section 10, Hildred Equity Partners II, LP, Hildred Equity Associates II, LP, Hildred Equity Partners II-FR, LP and Hildred Equity Partners II-A, LP, each a Delaware limited partnership, is made in favor of Revance Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (

AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER

Exhibit 2.1 AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of December 11, 2024 (this “Amendment”), by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub,” and tog

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA ME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC (Other) CROWN LABORATORI

AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER

Exhibit (d)(10) EXECUTION VERSION AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER This AMENDMENT TO THE AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER is made and entered into as of December 11, 2024 (this “Amendment”), by and among Crown Laboratories, Inc.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is being made only by the Offer to Purchase, dated December 12, 2024 (the “Offer to Purchase”) and the re

Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

Offer to Purchase All Outstanding Shares of Common Stock REVANCE THERAPEUTICS, INC. $3.10 per share, net in cash, without interest and less any required tax withholding Pursuant to the Offer to Purchase dated December 12, 2024 REBA MERGER SUB, INC. a

Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC.

Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A December 7, 2024

Execution Version Exhibit (d)(7) Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A December 7, 2024 Crown Laboratories, Inc.

Offer to Purchase All Outstanding Shares of Common Stock REVANCE THERAPEUTICS, INC. $3.10 per share, net in cash, without interest and less any required tax withholding Pursuant to the Offer to Purchase dated December 12, 2024 REBA MERGER SUB, INC. a

Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC.

Offer to Purchase All Outstanding Shares of Common Stock REVANCE THERAPEUTICS, INC. $3.10 per share, net in cash, without interest and less any required tax withholding REBA MERGER SUB, INC. a wholly owned subsidiary of CROWN LABORATORIES, INC.

Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of REVANCE THERAPEUTICS, INC.

Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share Board of Directors of Revance Recommend Stockholders Tender their Shares

Exhibit (a)(5)(L) Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.

Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) CROWN HOLDINGS INTERCO LLC CROWN LABORATORIES H

Exhibit 107 Calculation of Filing Fee Tables Schedule TO REVANCE THERAPEUTICS, INC.

Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners II, LP Hildred Equity Associates II, LP Hildred Equity Partners II-FR, LP Hildred Equity Partner

Exhibit (d)(6) Hildred Perennial Partners I, LP Hildred Capital Co-Invest-REBA, LP Hildred Equity Partners III, LP Hildred Equity Partners III-A Hildred Equity Partners II, LP Hildred Equity Associates II, LP Hildred Equity Partners II-FR, LP Hildred Equity Partners II-A, LP August 11, 2024 Crown Laboratories, Inc.

MUTUAL NONDISCLOSURE AGREEMENT

Exhibit (d)(5) MUTUAL NONDISCLOSURE AGREEMENT In connection with the consideration of a potential license, partnership or negotiated transaction (the “Transaction”) with Hildred Capital Management, LLC (herein, “Hildred Capital”) involving Crown Laboratories Holdings, Inc.

LETTER OF TRANSMITTAL to Tender Shares of Common Stock REVANCE THERAPEUTICS, INC. $3.10 per share, net in cash, without interest and less any required tax withholding Pursuant to the Offer to Purchase dated December 12, 2024 REBA MERGER SUB, INC. a w

Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of REVANCE THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 (December 11, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 (December 11, 2024) Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incor

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 ― Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative

Date: Monday, December 9

Exhibit 99.2 Date: Monday, December 9th To: All Employees Dear Revance Family, Today, we announced that we agreed to revised deal terms with Crown Laboratories and have entered into an amended and restated merger agreement. Following consummation of the pending merger, we believe the combined organization will be one of the leading global aesthetics and skincare companies, encompassing one of the

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 — Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative

AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT

Exhibit 10.1 Execution Version AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT This AMENDED AND RESTATED TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of December 7, 2024, is entered into by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and the stockholders of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Exhibit 99.1 Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement Johnson City and Nashville, Tenn. – December 9, 2024 ― Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA ME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off

Talking points for Crown Aesthetics Team

Exhibit 99.3 Talking points for Crown Aesthetics Team What should we communicate to HCPs when they ask: Why were Crown and Revance the best partners for this merger? What was the merger rationale? • Upon completion of the merger, we believe the combined company will be one of the leading global aesthetics and skincare companies, and encompass one of the most comprehensive portfolios of cutting-edg

AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among CROWN LABORATORIES, INC., REBA MERGER SUB, INC. REVANCE THERAPEUTICS, INC. Dated as of December 7, 2024

Exhibit 2.1 Execution Version AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among CROWN LABORATORIES, INC., REBA MERGER SUB, INC. and REVANCE THERAPEUTICS, INC. Dated as of December 7, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 3 1.1 Certain Definitions 3 1.2 Additional Definitions 17 1.3 Certain Interpretations 20 Article II THE OFFER 22 2.1 The Offer 22 2.2 Co

LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer; Nadeem Moiz, President, Chief Operating Officer and Chief Financial Officer DATE: December 9, 2024 RE: All Hands Company Update

Exhibit 99.2 LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer; Nadeem Moiz, President, Chief Operating Officer and Chief Financial Officer DATE: December 9, 2024 RE: All Hands Company Update Hello Crown Team, We are excited to announce that we have reached a revised deal with Revance Therapeutics. This marks a significant step forward in t

TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER This TWELFTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated December 5, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This ELEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated December 3, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Revance Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio

TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This TENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 29, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compa

NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER This NINTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 26, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 Revance Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Revance Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio

EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER This EIGHTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 19, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Com

SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER This SEVENTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 12, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Revance Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio

Fifth Amendment to Exclusive Distribution Agreement dated July 29, 2024 by and between Revance Therapeutics, Inc. and Teoxane SA

Fifth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated July 29th, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

Fourth Amendment to Exclusive Distribution Agreement dated June 13, 2024 by and between Revance Therapeutics, Inc. and Teoxane SA

Fourth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated June 13, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T

Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update –On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced. –Rev

SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER This SIXTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated November 1, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

, Revance Therapeutics, Inc. and Revance Australia Pty. Ltd.

Exhibit 10.2 EXCLUSIVE DISTRIBUTION AGREEMENT This EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”), dated as of October 24, 2024 (the “Effective Date”), is entered into by and between Revance Therapeutics, Inc., a Delaware corporation with its principal place of business at 1222 Demonbreun St., 20th Floor, Nashville, TN 37203 and Revance Australia Pty. Ltd., an Australia proprietary company wi

FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER This FIFTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 25, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

Sixth Amendment to Exclusive Distribution Agreement dated

Exhibit 10.1 Sixth Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated October 24, 2024 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 1222 Demonbreun Street, Suite 2000, Nashville, Tennessee 37203 (the Supplier and the Distributor, together the Parties, and each a Party) Preamble A. On

RVNC / Revance Therapeutics, Inc. / GIC Private Ltd - SC 13G/A Passive Investment

SC 13G/A 1 ef20037606sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) September 30, 2024 (Date of the Event Which Requires Filing of this Sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 Revance Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER This FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 18, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the ”Comp

RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER This THIRD WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 3, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Revance Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Revance Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER This SECOND WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated September 19, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Co

RVNC / Revance Therapeutics, Inc. / Beryl Capital Management LLC Passive Investment

SC 13G 1 rvnc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) September 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria

RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) August 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA ME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off

From: Mark Foley

Exhibit 99.1 From: Mark Foley Date: September 5, 2024 Subject: CEO Business Update Revance Family, I hope everyone had a great holiday weekend and that you found time to relax with family and friends. It has been a few weeks since our merger announcement, so I wanted to take time out to provide an update on important work that has been underway. While it is still early on, these are important foun

TO: Crown Associates FROM: Jeff Bedard, Founder & Chief Executive Officer DATE: September 5, 2024 RE: Update on Merger Agreement

Exhibit 99.1 TO: Crown Associates FROM: Jeff Bedard, Founder & Chief Executive Officer DATE: September 5, 2024 RE: Update on Merger Agreement Hi all, I hope you had a great holiday weekend and were able to find some time to relax with family and friends. As we close out the summer and head into fall, I would like to provide you with an update on some of the ways we’ve been working diligently on th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (

WAIVER TO AGREEMENT AND PLAN OF MERGER

Exhibit 99.1 WAIVER TO AGREEMENT AND PLAN OF MERGER This WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated August 27, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and waiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss

Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined c

Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA ME

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 REVANCE THERAPEUTICS, INC. (Name of Subject Company (issuer)) REBA MERGER SUB, INC. (Offeror) a wholly-owned subsidiary of CROWN LABORATORIES, INC. (Parent of Offeror) (Names of Filing Persons (identifying status as off

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Revance Therapeutics, Inc. (Name of Subject Company) Revance Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (

Employee FAQs

Exhibit 99.3 Employee FAQs These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement Q. Who is Crown Laboratories? A. Crown Laboratories, Inc. (“Crown”), is a privately held, global innovative leader in the skincare industry dedicated to developing and providing a diverse portfolio of safe and effective scientific solutions for life-long

CROWN CEO LETTER TO SALESFORCE TO: Crown Salesforce Team FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company & Customers

Exhibit 99.5 CROWN CEO LETTER TO SALESFORCE TO: Crown Salesforce Team FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company & Customers Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company. Today, we announced th

Salesforce FAQ’s Customer Facing Preparation

Exhibit 99.7 Salesforce FAQ’s Customer Facing Preparation How will this change impact my practice or my patients? • There will be no immediate impact – it will be business as usual – and we will continue to operate as independent companies until the deal closes. • Upon completion of the deal, Crown expects to have one of the most comprehensive portfolios of skin health and aesthetic brands – so we

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2024 Revance Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

All Employee CEO Memo

Exhibit 99.2 All Employee CEO Memo I am writing to share an important milestone and some very exciting news about our company, as we have taken a significant step forward in the future growth and development of Revance. Today we announced that Revance has agreed to merge with Crown Laboratories, a global innovative leader in the skincare industry. For background, Crown was started in 2000 by Jeff

CROWN CEO LETTER TO SUPPLIERS TO: Crown Suppliers FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company

Exhibit 99.4 CROWN CEO LETTER TO SUPPLIERS TO: Crown Suppliers FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company. Today, we announced that Crown has entere

Crown Laboratories and Revance Announce Entry Into Merger Agreement

Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar

KEY MESSAGES

Exhibit 99.2 KEY MESSAGES GENERAL MESSAGING (FOR EXTERNAL + INTERNAL AUDIENCES) Business Rationale • Crown Laboratories (“Crown”), a global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), an aesthetics company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician

CROWN CEO LETTER TO CUSTOMERS TO: Crown Customers & KOLs FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company

Exhibit 99.6 CROWN CEO LETTER TO CUSTOMERS TO: Crown Customers & KOLs FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Hi X, I am writing to share some exciting news about our company, as we have taken a significant step forward in our vision to become a fully integrated global skincare company with safe and effective scientific

Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined c

Exhibit 99.1 Crown Laboratories and Revance Announce Entry Into Merger Agreement Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company’s flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizar

CROWN CEO LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company

Exhibit 99.3 CROWN CEO LETTER TO EMPLOYEES TO: Crown Laboratories Employees FROM: Jeff Bedard, Founder and Chief Executive Officer DATE: August 12, 2024 RE: Exciting Development for Our Company Crown Family, I am writing to share some very exciting news about our company, as we have taken a significant step forward in our vision to become a leading global aesthetics and skincare company. Today we

Support Agreement, dated as of August 11, 2024, by and among Crown Laboratories, Inc., Reba Merger Sub, Inc. and the parties named on Schedule A thereto (included as Exhibit C in the Merger Agreement and incorporated herein by reference)

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Crown Laboratories, Inc. Reba Merger Sub, Inc. and Revance Therapeutics, Inc. August 11, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 14 1.3 Certain Interpretations 16 Article II THE OFFER 18 2.1 The Offer 18 2.2 Company Action 21 Article III THE MERGER 22 3.1 The Mer

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therap

Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update –Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. –Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. –Q2 DAXXIFY aesthetic units sold increased 65% YoY and 15% QoQ; over 3,700 ordering accounts reached. –Q2 RHA Collection net revenue of $36.

ween Revance Therapeutics, Inc. and Erica Jordan

Exhibit 10.4 1222 Demonbreun Street, 20th Floor Nashville, TN 37203 www.Revance.com February 21, 2023 Erica Jordan Via Electronic Delivery Dear Erica, We are pleased to offer you the position of Senior Vice President, Strategy at Revance (the “Company”), reporting directly to Dustin Sjuts, President. We look forward to the significant contributions you will make at Revance as we continue to grow a

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update –Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. –DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. –Toxin market share increased from 3.0% in Q4’23 to 3.7% in Q1’24. –Aesthetic units sold increas

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

ffer Letter dated September 29, 2022 by and between Revance Therapeutics, Inc. and David Hollander

Exhibit 10.3 1222 Demonbreun Street, 20th Floor Nashville, TN 37203 www.Revance.com September 29, 2022 David A. Hollander, MD [email protected] via Electronic Delivery Dear David, Subject to approval by Compensation Committee of the Board, we are pleased to offer you the position of Chief Medical Officer at Revance (the “Company”), reporting directly to Dustin Sjuts, President. We loo

Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.6 Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Revance Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Exhibit 99.2 Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia –DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 –Revance has received a Permanent J-Code and has already secured coverage for 78% of comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Thera

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

RVNC / Revance Therapeutics, Inc. / JPMORGAN CHASE & CO - FILING REVANCE THERAPEUTICS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

16,000,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275548 PROSPECTUS SUPPLEMENT (To Prospectus dated November 14, 2023) 16,000,000 Shares Common Stock We are offering 16,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “RVNC.” On March 4, 2024, the last reported sale price of our common stoc

Calculation of Filing Fee Tables (Form Type) Revance Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revance Therapeutics, Inc.

Underwriting Agreement, dated March 4, 2024, by and between the Company and the Underwriter

Exhibit 1.1 Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement March 4, 2024 BARCLAYS CAPITAL INC. As representative (the “Representative”) of the several Underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, NY 10019 Ladies and Gentlemen: Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Revance Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissio

SUBJECT TO COMPLETION, DATED MARCH 4, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275548 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Revance Therapeutics, Inc.

List of Subsidiaries of the Registrant

Exhibit 21.1 REVANCE THERAPEUTICS, INC. LIST OF SUBSIDIARIES 1.Hint, Inc. (d/b/a HintMD), incorporated in Delaware.

, 2024, by and between Revance Therapeutics, Inc. and Dustin Sjuts

Exhibit 10.2 February 23, 2024 (the “Execution Date”) Electronic Mail Dustin S. Sjuts Revance Therapeutics, Inc. Re: Separation Agreement Dear Dustin: This letter sets forth the substance of the mutual separation agreement (the “Agreement”) that Revance Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.SEPARATION DATE. Your last day of work as the Compan

Revance Therapeutics, Inc. Incentive Compensation Recoupment Policy

Exhibit 97.1 Revance Therapeutics, Inc. Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Revance Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Pol

Revance Therapeutics, Inc. 202

Exhibit 10.32 REVANCE THERAPEUTICS, INC. 2024 MANAGEMENT BONUS PROGRAM On February 7, 2024, upon recommendation of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Revance Therapeutics, Inc. (the “Company”), the Board approved the Company’s 2024 corporate objectives, weighted for purposes of determining bonuses, if any, for the Company’s executive officers wi

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update –Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. –Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reordering accounts. –2024 pr

Exhibit 4.4

Exhibit 4.4 DESCRIPTION OF REVANCE THERAPEUTICS, INC. SECURITIES The following is a description of the common stock, $0.001 par value (the “Common Stock”), of Revance Therapeutics, Inc. (“we” or the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). General Our Amended and Restated Certifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therapeuti

Amendment No. 2 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated February

Exhibit 10.1 AMENDMENT NO. 2 TO THE TECHNOLOGY TRANSFER, VALIDATION AND COMMERCIAL FILL/FINISH SERVICES AGREEMENT THIS AMENDMENT NO. 2 (this “Amendment”) is made and entered into as of February 23, 2024 (the “Amendment Effective Date”), by and between Revance Therapeutics, Inc., (“Client”), and Ajinomoto Althea, Inc., dba Ajinomoto Bio-Pharma Services, a California (formerly Delaware) corporation

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi

RVNC / Revance Therapeutics, Inc. / Palo Alto Investors LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event which Re

RVNC / Revance Therapeutics, Inc. / Antara Capital LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 761330109 (CUSIP Number) December 3

Amended and Restated Executive Severance Benefit Plan

REVANCE THERAPEUTICS, INC. EXECUTIVE SEVERANCE BENEFIT PLAN Amended and Restated Effective February 7, 2024 1. INTRODUCTION. This Revance Therapeutics, Inc. Executive Severance Benefit Plan (the “Plan”) is established by Revance Therapeutics, Inc. (the “Company”). The Plan was originally adopted by the Board on December 17, 2013; became effective without further action on the IPO Date (as defined

RVNC / Revance Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01818-revancetherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Revance Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 761330109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

RVNC / Revance Therapeutics, Inc. / Polar Capital Holdings Plc Passive Investment

SC 13G/A 1 polar-rvnc123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

RVNC / Revance Therapeutics, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

RVNC / Revance Therapeutics, Inc. / GIC Private Ltd - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of the Event Which Requires Filing of this Statement) Check the appropriate box to desig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

RVNC / Revance Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment

SC 13G 1 reva23in.htm CUSIP NO. 761330109 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing

RVNC / Revance Therapeutics, Inc. / JPMORGAN CHASE & CO - FILING REVANCE THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 RevanceTherapeuticsInc.h.htm FILING REVANCE THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which

RVNC / Revance Therapeutics, Inc. / JPMORGAN CHASE & CO - FILING REVANCE THERAPEUTICS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Exhibit 99.1 Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook –Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. –Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 millio

Amended and Restated Bylaws

AMENDED AND RESTATED BYLAWS OF REVANCE THERAPEUTICS, INC. (A DELAWARE CORPORATION) (Approved and Adopted December 12, 2023) TABLE OF CONTENTS ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings. 1 Section 6. Special Meeting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on November 14, 2023

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on November 14, 2023 Registration No.

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association]

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Revance Therapeutics, Inc.

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 Exhibit 4.8 REVANCE THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF REVANCE THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T

First Amendment to the Note Purchase Agreement, dated August 8, 2023 among Revance Therapeutics, Inc., certain subsidiaries of Revance Therapeutics, Inc., Athyrium Buffalo LP and the purchasers from time to time party thereto

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update –Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. –Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. –Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. –In August, DAXXIFY was approved by the FDA for the treatment of ce

RVNC / Revance Therapeutics Inc / Teoxane SA - SC 13D/A Activist Investment

SC 13D/A 1 ef20013034sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) Patrice Calvayrac Chief Financial Officer Teoxane SA Rue de Lyon 105 CH

Revance Provides Corporate Update at Investor Day

EX-99.1 Exhibit 99.1 Revance Provides Corporate Update at Investor Day NASHVILLE, Tenn. – (BUSINESS WIRE) – September 19, 2023—Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30am ET to 12:00pm ET. The Investor Day will include management presentations on Revance’s vision and strategy, Revance Aesthetics overview an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2023 Revance Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Comm

INVESTOR DAY 2023 WELCOME MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience

Exhibit 99.2 INVESTOR DAY 2023 The presentations today contain information about Revance’s business for stockholders, potential investors, and financial analysts. The content shared is intended for this audience only. INVESTOR DAY 2023 WELCOME MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience INVESTOR DAY 2023 PR O GR A M REVANCE AESTHETICS DAXXIFY® KOL PANEL B R E AK REVANCE

RVNC / Revance Therapeutics Inc / Teoxane SA - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) Patrice Calvayrac Chief Financial Officer Teoxane SA Rue de Lyon 105 CH 1203 Geneva, Switzerland +41 22 344 96 36

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therap

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update –Q2 total revenue of $58.1 million, a YoY increase of 104.9%. –Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%. –Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%. –Bolstered financial position with $100 million net proceeds from ATM program and $50 million in notes availa

by and between Revance Therapeutics, Inc. and

THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (the “Amendment”) is made effective as of the last date of execution on the signature page hereto (the “Effective Date”), by and between 1222 DEMONBREUN, LP, a Texas limited partnership (“Landlord”), and REVANCE THERAPEUTICS, INC.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

March 23, 2023, by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Dustin Sjuts President [*] March 22, 2023 By Email & Federal Express Ning Yuan [*] Re: Second Letter Amendment to the License Agreement Dear Ning, As you are aware, Revance Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Thera

License and Service Agreement dated February 8, 2007, by and between Revance Therapeutics, Inc. and List Biological Laboratories, Inc.

EXECUTION COPY LICENSE AND SERVICE AGREEMENT This License and Service Agreement (together with any Attachments hereto, the "Agreement") is entered into as of February 8, 2007 (the "Effective Date"), by and between Revance Therapeutics, Inc.

Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update –Q1 total revenue of $49.3 million, a YoY increase of 95.3%. –Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%. –Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch. –FDA approves Ajinomoto Biopharma Services, Revance’s contract manufacturer for DAXXIFY®. –Fosun Pharm

First Addendum to the License and Service Agreement dated April 21, 2009, by and between Revance Therapeutics, Inc. and List Biological Laboratories, Inc.

FIRST ADDENDUM TO LICENSE AND SERVICE AGREEMENT THIS FIRST ADDENDUM ("First ·Addendum"), is made and entered into, effective as of April 21, 2009 ("First Addendum Date"), by and between Revance Therapeutics, Inc.

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Revance Therapeutics, Inc.

Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update –Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. –Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. –DAXXIFY® Q4 PrevU revenue of $11.0 million,

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi

Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Exhibit 99.2 Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director –Dr. Coric currently serves as the Chairman and Chief Executive Officer of Biohaven (BHVN) - NASHVILLE, Tenn.,-(BUSINESS WIRE)— February 28, 2023 - Revance Therapeutics, Inc. (RVNC, www.revance.com), announced today the appointment of Dr. Vlad Coric

Revance Therapeutics, Inc. 202

Exhibit 10.31 REVANCE THERAPEUTICS, INC. 2023 MANAGEMENT BONUS PROGRAM On February 1, 2023, the Compensation Committee of the Board of Directors of Revance Therapeutics, Inc. (the “Company”) approved the Company’s 2023 corporate objectives, weighted for purposes of determining bonuses, if any, for the Company’s executive officers with respect to 2023 performance (the “2023 Bonus Program”). The 202

Third Amendment to Exclusive Distribution Agreement dated December 22, 2022, by and between Revance Therapeutics, Inc. and Teoxane SA

Exhibit 10.46 Third Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated December 16, 2022 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 7555 Gateway Boulevard Newark, California, USA (the Supplier and the Distributor, together the Parties, and each a Party) CERTAIN CONFIDENTIAL CERTAIN

Form of Restricted Stock Unit Award Agreement and Grant Notice for Revance Therapeutics, Inc. 2014 Equity Incentive Plan

Exhibit 99.2 Mandatory Sell to Cover Form Revance Therapeutics, Inc. Restricted Stock Unit Grant Notice (2014 Equity Incentive Plan) Revance Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”)

Exhibit 4.4

Exhibit 4.4 DESCRIPTION OF REVANCE THERAPEUTICS, INC. COMMON STOCK The following is a description of the common stock, $0.001 par value (the “Common Stock”), of Revance Therapeutics, Inc. (“we” or the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). General Our Amended and Restated Certi

Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance Therapeuti

Form of Restricted Stock Unit Agreement and Grant Notice under Amended and Restated Revance Therapeutics, Inc. 2014 Inducement Plan

Sell to Cover RSU Grant Package Revance Therapeutics, Inc. Restricted Stock Unit Grant Notice (2014 Inducement Plan) Revance Therapeutics, Inc. (the “Company”), pursuant to Section 6(b) of the Company’s 2014 Inducement Plan (the “Plan”), hereby awards to Participant, as an inducement material to Participant’s entering into employment with the Company, a Restricted Stock Unit Award for the number o

As filed with the Securities and Exchange Commission on February 28, 2023

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

RVNC / Revance Therapeutics Inc / Antara Capital LP - SC 13G Passive Investment

SC 13G 1 d431111dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 76

RVNC / Revance Therapeutics Inc / Polar Capital Holdings Plc Passive Investment

SC 13G 1 polar-rvnc123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap

JOINT FILING AGREEMENT

EX-99.1 2 d431111dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing of Antara Capital LP, Antara Capital GP LLC and Himanshu Gulati, on behalf of each of them of any filing required by such party under

RVNC / Revance Therapeutics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

RVNC / Revance Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01792-revancetherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Revance Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 761330109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

RVNC / Revance Therapeutics Inc / GIC Private Ltd - SC 13G/A Passive Investment

SC 13G/A 1 brhc10047710sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 31, 2022 (Date of the Event Which Requires Filing of this St

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

RVNC / Revance Therapeutics Inc / JPMORGAN CHASE & CO - FILING REVANCE THERAPEUTICS, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* Revance Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 761330109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Exhibit 99.1 Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results •DAXXIFY® PrevU program off to strong start with ~400 select practice partners and thousands of patients treated, generating positive feedback and strong, early uptake •Preliminary unaudited Q4 DAXXIFY® revenue from PrevU of between $10.5 million and $11.5 milli

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commiss

RVNC / Revance Therapeutics Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Revance Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761330109 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

Second Amendment to Exclusive Distribution Agreement dated November 18, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA

Exhibit 10.1 Second Amendment to the Exclusive Distribution Agreement dated January 10, 2020 dated November 18, 2020 by and among Teoxane SA (the Supplier) Rue de Lyon 105, CH-1203 Geneva, Switzerland and Revance Therapeutics Inc. (the Distributor) 7555 Gateway Boulevard Newark, California, USA (the Supplier and the Distributor, together the Parties, and each a Party) Preamble A.On January 10, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36297 Revance T

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update ?Received FDA approval for DAXXIFY? (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines ?Q3 total revenue of $29.0 million, a YoY increase of 47% with RHA? Collection revenue of $26.1 million, a YoY increase of 43% ?Aesthetic accounts across products and services totaled over 4,50

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commis

8,000,000 Shares Common Stock $25.00 per share

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250998 PROSPECTUS SUPPLEMENT (To Prospectus dated November 27, 2020) 8,000,000 Shares Common Stock $25.00 per share We are offering 8,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?RVNC.? On September 12, 2022, the last reported sale price of our common stock on The

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Comm

Underwriting Agreement, dated September 12, 2022, by and among the Company and the Underwriters

EX-1.1 2 d404755dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION Revance Therapeutics, Inc. Common Stock, par value $0.001 per share Underwriting Agreement September 12, 2022 Goldman Sachs & Co. LLC Cowen and Company, LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, N

Calculation of Filing Fee Tables (Form Type) Revance Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revance Therapeutics, Inc.

Subject to Completion, Dated September 12, 2022

424B5 1 d359293d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-250998 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commi

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36297 77-0551645 (State or other jurisdiction of incorporation) (Commissi

Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update

Exhibit 99.1 Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update ?PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines ?Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines ?Second quarter total revenue of $28.4 million, with RHA? Collection rev